San Rocco Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1993-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.errantgene.com
Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
Phase 1
Active, not recruiting
- Conditions
- Confirmed Diagnosis of ß-thalassemia Major
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- San Rocco Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT01639690
- Locations
- 🇮🇹
Hospital "V.Cervello" Uoc Ematologiaii E Malattie Rare, Palermo, Italy
News
No news found